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Abstract (236/250) 
Introduction: There are little data on the usefulness of different tests to diagnose asthma in children. 
Aim: We assessed the contribution of a detailed history and a variety of diagnostic tests for diagnosing 
asthma in children. 
Methods: We studied children aged 6-16 years referred consecutively for evaluation of suspected 
asthma to two pulmonary outpatient clinics. Symptoms were assessed by parental questionnaire. The 
clinical evaluation included skin prick tests, measurement of fractional exhaled nitric oxide (FeNO), 
spirometry, bronchodilator reversibility and bronchial provocation tests (BPT) by exercise, 
methacholine, and mannitol. Asthma was diagnosed by the physicians at the end of the visit. We 
assessed diagnostic accuracy of symptoms and tests by calculating sensitivity, specificity, positive and 
negative predictive values, and area under the curve (AUC). 
Results: Of the 111 participants, 80 (72%) were diagnosed with asthma. The combined sensitivity and 
specificity was highest for reported frequent wheeze (>3 attacks/year) (sensitivity 0.44-specificity 0.90), 
awakening due to wheeze (0.41-0.90), and wheeze triggered by pollen (0.46-0.83) or by pets (0.29-
0.99). Of the diagnostic tests, the AUC was highest for FeNO measurement (0.80) and BPT by 
methacholine (0.81) or exercise (0.74), and lowest for FEV1 (0.62) and FEV1/FVC (0.66), assessed by 
spirometry. 
Conclusion: This study suggests that specific questions about triggers and severity of wheeze, 
measurement of FeNO and BPT by methacholine or exercise contribute more to the diagnosis of asthma 
in school-aged children than spirometry, bronchodilator reversibility and skin prick tests. 
  
Introduction 
Diagnosing asthma in children is not straightforward, because we lack a stand-alone diagnostic test. 
Symptoms (cough, wheeze, breathlessness) are not specific for asthma and interpretation of commonly 
used diagnostic tests is complicated by the temporal variability and phenotypic heterogeneity of 
asthma. Diagnostic guidelines thus suggest diagnosing asthma based on a characteristic pattern of 
respiratory symptoms, clinical examination, demonstration of reversible airway obstruction assessed by 
spirometry and airway inflammation measured by FeNO [1-4]. Allergy tests and measurement of 
bronchial hyperresponsiveness by direct and indirect challenge tests are used as further aids for 
diagnosis.  
However, the diagnostic algorithm proposed by recent guidelines has been questioned for children and 
there are surprisingly little data available to assess the usefulness of the different tests in the diagnosis 
of asthma in school-aged children [5]. Systematic literature reviews done for recent guidelines and for 
the ongoing taskforce of the European Respiratory Society identified only a handful of publications 
assessing the accuracy of the different tests for children with suspected asthma [2, 3]. Most publications 
identified by the searches had a case-control design, comparing children with asthma to healthy 
controls instead of consecutive referrals of children suspected of having asthma. Available studies had 
included only few diagnostic tests and no detailed history, and asthma diagnosis used as reference 
standard was often poorly defined or too narrow, for instance including only allergic asthma. Also, 
papers used different cut-offs for positive tests (e.g. for FeNO or FEV1), and it remains unclear which 
cut-offs are best for children [1-4]. In this study, we assessed the diagnostic accuracy of reported 
respiratory symptoms and different objective tests to diagnose asthma in consecutive referrals of 
school-aged children presenting symptoms suggestive of asthma. 
  
Methods 
Study population and study design 
For this study, we re-analysed data from a clinical study done in 2007-2008 in Switzerland. It included 
consecutive first time referrals to the respiratory outpatient clinics of two paediatric hospitals (St. 
Gallen and Basel) of 6-16 year old children for evaluation of a possible asthma diagnosis with a history 
of wheezing, dyspnoea or cough. Children were excluded from the study if they had a known chronic 
respiratory disease such as cystic fibrosis, or a respiratory tract infection during the four weeks prior to 
the visit. The aim of the initial study had been to compare the results of mannitol challenge tests to 
exercise challenge tests [6]. 
 
Study procedures 
All children referred for the first time by general practitioners or primary care paediatricians for 
evaluation of possible asthma were invited to participate in the study, which included two visits to the 
hospital within a week (figure 1). At the first visit, all children underwent clinical evaluation, skin prick 
testing (unless printed results of a skin prick test done  during the past 2 years were available), 
measurement of FeNO, spirometry, exercise BPT, methacholine BPT and bronchodilator reversibility 
test, in that order. Children who reacted to the exercise challenge and received salbutamol returned for 
an extra visit within the next few days to perform the methacholine challenge test. Within a week all 
children repeated the FeNO measurement and performed a mannitol BPT. Between visits, the family 
completed a questionnaire. Ethical approval was obtained from the local Ethics committee and all 
parents gave informed consent at baseline (EKSG 07/001). 
 
Clinical asthma diagnosis (reference standard) 
The study physicians, experienced paediatric pulmonologists, completed a physician’s report form that 
included the clinical diagnosis (definite asthma, probable asthma or other disease), at two time points. 
At the first visit, physicians considered only medical history, clinical examination, allergy tests, FeNO 
measurement and spirometry. At the second visit, the same physician reported the clinical diagnosis (as 
definite asthma, probable asthma or other disease) in the second physicians’ report form, taking into 
account all the information available, i.e. medical history, clinical examination, allergy tests, FeNO 
measurement, spirometry and also results of the bronchial provocation tests and bronchodilator 
reversibility test. For our main analysis, we defined asthma (reference standard) as an affirmative 
answer to either definite or probable asthma in the second physician’s report form. In a sensitivity 
analysis, we used the first physicians’ report form (based on all the information except the BPTs) to 
define asthma (reference standard). 
 
Assessment of respiratory symptoms and diagnostic testing 
The parental questionnaire included the ISAAC key questions for lower respiratory symptoms and more 
detailed questions on wheeze and cough derived from the questionnaires used in the Leicester 
respiratory cohort studies (see supplementary material) [7, 8]. All diagnostic tests were performed 
according to published guidelines [9-13]. Children withheld short acting beta2-agonists for 8 hours, 
inhaled corticosteroids, leukotriene antagonists, and long acting beta2-agonists for 24 hours, and 
antihistamines and sodium cromoglycate for >72 hours. 
 
Skin prick test 
We performed skin prick tests using birch, grass, mugwort, alternaria, cat, house dust mites (D. 
pteronyssinus), histamine and saline. A wheal size of ≥3 mm was considered positive in case the positive 
control (histamine) had a wheal size of ≥3 mm and the negative control (saline) had a wheal size of 
<3mm. These allergens cover 95% of allergies to inhaled allergens in Switzerland [14]. 
 
Fractional exhaled nitric oxide 
Fractional exhaled nitric oxide (FeNO) was measured in doublets before spirometry, using the portable 
multi-gas analyser (NIOX MINO®, Aerocrine, Sweden), in accordance with published guidelines [10] and 
previous studies using this device [15, 16]. The portable analyser ensures a constant expiratory flow of 
50±5 ml/s, has an accuracy of ±10% with a minimum of ±5 ppb and the quality was controlled by the 
lung function technician according to the manufacturer’s guidelines. 
 
Spirometry 
Spirometry was performed using American Thoracic Society (ATS) criteria for paediatric lung function 
testing and a Jaeger masterscope (Erich Jaeger GmbH, Würzburg, Germany), using JLAB software 
(version 4.34). Spirometry was done in triplicate by experienced lung function technicians, who 
performed quality control during the measurement, and recorded the best measurement. The flow-
volume curve was then also checked by the responsible paediatric pulmonologist. Results are expressed 
as proportion (FEV1/FVC) and as z-scores based on GLI-2012 reference standards [17]. 
 
Bronchial provocation tests 
For all bronchial provocation tests, baseline FEV1 was measured in triplicate using ATS criteria for 
paediatric lung function testing [9] and the best measurement was recorded. We reported the results of 
the exercise BPT as the maximum fall of FEV1 compared to baseline, the methacholine BPT as 
provocation dose causing a 20% decrease of FEV1 from baseline (PD20) and the mannitol BPT as 
provocation dose causing a 15% decrease of FEV1 from baseline (PD15). After the methacholine BPT, all 
children were given 4 puffs of salbutamol 100 g to test for bronchodilator reversibility. Children also 
received salbutamol if 15 minutes after the exercise or mannitol BPT, FEV1 had not returned within 5% 
of baseline or in case of dyspnoea. More details on the bronchial provocation tests have been published 
before and can be found in the supplementary material [6]. 
 
Statistical analysis 
For the reported respiratory symptoms and the different tests, we calculated sensitivity, specificity, 
positive predictive value and negative predictive value, Youden’s Index (sensitivity + specificity -1), area 
under the curve (AUC) and their 95% confidence intervals (CI) to diagnose asthma, using the final (post 
BPT) physicians diagnosis as reference standard. We did a sensitivity analysis using the first (pre BPT) 
physicians’ diagnosis. We displayed the cut-off values with the highest Youden’s index in our study and 
those used in the literature. We used STATA software (version 15; College Station, Texas) for statistical 
analysis.  
 
Results  
Characteristics of the study population  
Of the 124 children invited, 111 (90%) were recruited, 84 from St. Gallen and 27 from Basel. The median 
age was 12 years (range 6-16) and 62% were male. Most children were referred with wheeze and cough 
(47%) or wheeze without cough (23%). Inhaled medication had been used by 64% prior to referral, 
including 19% who had used inhaled corticosteroids (table 1). Of the 111 participants, 80 (72%) were 
diagnosed with asthma after all BPTs were done compared to 94 (85%) before the BPTs were done. The 
remaining children were diagnosed with cough unrelated to asthma (8% before BPTs and 13% after 
BPTs), and with inducible laryngeal obstruction and dysfunctional breathing (6% before BPTs and 7% 
after BPTs) (table S1). None of the children was diagnosed with a severe lung disease such as Cystic 
Fibrosis [18]. 
 
  
Table 1. Characteristics of the study participants (N=111) 
 Total 
n% 
     Age,  median (range) 11  (6-16) 
     Sex, male 69 (62) 
Respiratory symptoms in the last 12 months   
     Any wheeze 80   (72) 
     More than 3 attacks of wheeze 38   (34) 
     Wheeze with colds 43    (39) 
     Wheeze apart from colds 67    (60) 
     Exercise-induced wheeze 70    (63) 
     Wheeze triggered by pollen 36    (32) 
     Wheeze triggered by house dust 21    (19) 
     Wheeze triggered by pets 20    (18) 
     Awakening due to wheeze 36    (32) 
     Cough longer than 4 weeks 21 (19) 
     Night cough 48    (43) 
     Cough more than others 37 (33) 
     Dyspnoea 25    (23) 
     Hay fever* 49  (44) 
     Eczema* 26  (23) 
Inhaled medication   
     Any 71 (64) 
     Short-acting B2-agonist, alone 49 (44) 
     ICS + short-acting B2-agonist 6 (5) 
     ICS + long-acting B2-agonist 16 (14) 
*Ever in the past, ICS = inhaled corticosteroids 
 
Diagnostic accuracy of respiratory symptoms to diagnose asthma 
Reported wheeze in the past 12 months had the highest sensitivity (80%) for physician diagnosed 
asthma (table 2). Specificity was highest for frequent (>3 attacks/year) wheeze (90%), awakening due to 
wheeze (90%), and wheeze triggered by pollen (83%), house dust (93%) or pets (99%). Combined 
sensitivity and specificity was highest for frequent wheeze in the past 12 months (Youden’s index 0.34), 
awakening due to wheeze (0.31) and wheeze triggered by pollen (0.29) or pets (0.28) (table 2).  
 
  
Table 2. Diagnostic accuracy of respiratory symptoms to diagnose asthma N=111 
 A+S+ 
n 
A-S+ 
n 
A+S- 
n 
A-S- 
n 
Sens 
%  
(95%CI) 
Spec 
%  
(95%CI) 
PPV 
%  
(95%CI) 
NPV 
%  
(95%CI) 
YI 
Respiratory symptoms 
in the past 12 months 
         
Any wheeze 64 16 16 15 80 (70-88) 48 (30-67) 80 (70-88) 48 (30-67) 0.28 
> 3 attacks of wheeze 35 3 45 28 44 (33-55) 90 (74-98) 92 (79-98) 38 (27-50) 0.34 
Wheeze with colds 32 11 48 20 40 (29-52) 65 (45-81) 74 (59-86) 29 (19-42) 0.05 
Wheeze apart from colds 54 13 26 18 68 (56-78) 58 (39-75) 81 (69-89) 41 (26-57) 0.26 
Exercise-induced wheeze 54 16 26 15 68 (56-78) 48 (30-67) 77 (66-86) 37 (22-53) 0.16 
Wheeze triggered by          
     Pollen 31 5 37 24 46 (33-58) 83 (64-94) 86 (71-95) 39 (27-53) 0.29 
     House dust 19 2 46 26 29 (19-42) 93 (76-99) 90 (70-99) 36 (25-48) 0.22 
     Pets 20 0 50 17 29 (18-41) 99 (80-99) 99 (83-99) 25 (16-37) 0.28 
Awakening due to wheeze 33 3 47 28 41 (30-53) 90 (74-98) 86 (71-95) 37 (26-49) 0.31 
Cough > 4 weeks 11 10 68 21 14   (7-24) 68 (49-83) 52 (30-74) 24 (15-34) -0.18 
Night cough 38 10 42 20 48 (36-59) 67 (47-83) 79 (65-90) 32 (21-45) 0.15 
Cough more than others 28 9 52 21 35 (25-46) 70 (51-85) 76 (59-88) 29 (19-41) 0.05 
Dyspnoea 21 4 58 26 27 (17-38) 87 (69-96) 84 (64-95) 31 (21-42) 0.14 
Hay fever* 40 9 38 22 51 (40-63) 71 (52-86) 82 (68-91) 37 (25-50) 0.22 
Eczema* 21 5 58 25 27 (17-38) 83 (65-94) 81 (61-93) 30 (21-41) 0.10 
A+S+ = children with asthma diagnosis and reported symptom, A-S+ = children without asthma diagnosis but with 
symptom, A+S- = children with asthma diagnosis but without symptom, A-S- = children without asthma and 
without symptom, Sens = sensitivity, Spec = specificity, PPV = positive predictive value, NPV = negative predictive 
value YI = Youden’s-Index = Sensitivity + Specificity -1, *Ever in the past 
 
Diagnostic accuracy of tests to diagnose asthma 
All 111 children completed SPT, FeNO, spirometry and BPT by mannitol. BPT by exercise could not be 
completed in 12 children because of exhaustion (N=7), inspiratory stridor (induced laryngeal 
obstruction) (N=2), no cooperation (N=2) or technical difficulties (N=1) [6, 19]. Seven patients could not 
complete BPT by methacholine due to exhaustion and 36 children performed the test during an extra 
visit a few days later. In four patients the skin prick test result was not considered valid because the 
histamine control was not positive. Test results in patients with and without asthma diagnosis are 
displayed in table S2. 
 
The cut-off values with the best diagnostic accuracy were <80% for FEV1/FVC, ≤-0.8 z-score for FEV1, 
≥8% decrease of FEV1 for BPT by exercise, PD-20 <0.7mg for BPT by methacholine, PD-15 <635mg for 
BPT by mannitol, ≥2 for the number of positive skin prick tests, ≥8mm for the cumulative wheel size of 
skin prick tests, and ≥21ppb for FeNO (table 3). 
Accuracy overall was best for FeNO, BPT by methacholine and BPT by exercise (AUC 0.80, 0.81, 0.74 
respectively). Accuracy was lower for BPT by mannitol, and skin prick test (AUC around 0.70), and 
lowest for spirometry (AUC 0.66 and 0.62 for FEV1 and FEV1/FVC respectively) (figure 2). 
 
Table 3. Diagnostic accuracy of clinical tests to diagnose asthma N=111 
 A+T+ 
n 
A-T+ 
n 
A+T- 
n 
A-T- 
n 
Sens 
%  
(95%CI) 
Spec 
%  
(95%CI) 
PPV 
%  
(95%CI) 
NPV 
%  
(95%CI) 
YI AUC 
Clinical tests           
Skin prick test1          0.70 
     ≥1 positive test 69 18 8 12 90 (81-95) 40 (23-59) 79 (69-87) 60 (32-81) 0.30  
     ≥2 positive tests* 61 14 16 16 79 (68-88) 53 (34-72) 81 (71-89) 50 (32-68) 0.32  
Skin prick test2          0.72 
     ≥4 mm 63 16 12 14 84 (74-91) 47 (28-66) 80 (69-88) 54 (33-73) 0.31  
     ≥8 mm* 46 7 29 23 61 (49-72) 77 (58-90) 87 (75-95) 44 (30-59) 0.38  
FeNO          0.80 
     ≥21ppb* 47 4 33 27 59 (47-70) 87 (70-96) 92 (81-98) 45 (32-58) 0.46  
     ≥22ppb 44 4 36 27 55 (43-66) 87 (70-96) 92 (80-98) 43 (30-56) 0.42  
     ≥25ppb 40 2 40 29 50 (39-61) 94 (79-99) 95 (84-99) 42 (30-55) 0.44  
     ≥35ppb 31 2 49 29 39 (28-50) 94 (79-99) 94 (80-99) 37 (26-49) 0.33  
Spirometry           
  FEV1/FVC          0.66 
     <70% 6 0 74 30 8   (3-16) 99 (88-99) 99 (54-99) 29 (20-39) 0.08  
     <80%* 37 2 43 28 46 (35-58) 93 (78-99) 95 (83-99) 39 (28-52) 0.40  
     <90% 66 22 14 8 83 (72-90) 27 (12-46) 75 (65-84) 36 (17-59) 0.09  
  FEV1          0.62 
     ≤-0.8* 35 7 45 24 44 (33-56) 77 (59-90) 83 (69-93) 35 (24-47) 0.21  
     ≤-1.0 28 5 52 26 35 (25-47) 84 (66-95) 85 (68-95) 33 (23-45) 0.19  
Bronchodilator rev.          0.58 
  ≥10% increase FEV1* 20 3 54 26 27 (17-39) 90 (73-98) 87 (66-97) 33 (22-44) 0.17  
  ≥12% increase FEV1 16 3 58 26 22 (13-33) 90 (73-98) 84 (60-97) 31 (21-42) 0.11  
BPT           
 Exercise          0.74 
   ≥8% decrease FEV1* 47 5 28 19 63 (51-74) 79 (58-93) 90 (79-97) 40 (26-56) 0.42  
   ≥10% decrease FEV1 39 4 36 20 52 (40-64) 83 (63-95) 91 (78-97) 36 (23-50) 0.35  
   ≥12% decrease FEV1 33 2 42 22 44 (33-56) 92 (73-99) 94 (81-99) 34 (23-47) 0.36  
 Methacholine          0.81 
   PD-20 <0.7mg* 62 8 13 21 83 (72-90) 72 (53-87) 89 (79-95) 62 (44-78) 0.55  
   PD-20 <1mg 64 9 11 20 85 (75-92) 69 (49-85) 88 (78-94) 65 (45-81) 0.54  
 Mannitol          0.68 
   PD-15 <635 mg* 31 1 49 30 39 (28-50) 97 (83-99) 97 (84-99) 38 (27-50) 0.36  
A+T+ = children with asthma diagnosis and positive test result, A-T+ = children without asthma diagnosis but 
positive test result, A+T- = children with asthma diagnosis but negative test result, A-T- = children without asthma 
and negative test result, Sens = sensitivity, Spec = specificity, PPV = positive predictive value, NPV = negative 
predictive value, YI = Youden’s-Index = Sensitivity + Specificity -1, AUC = area under the curve, FeNO = fractional 
exhaled nitric oxide, ppb = parts per billion, FEV1 = forced expiratory volume in 1 second, FVC = forced vital 
capacity, Bronchodilator rev. = bronchodilator reversibility, BPT = bronchial provocation test  
Cut-offs chosen based on proposed cut-offs from previous publications 
*Cut-off with maximum combined sensitivity and specificity (highest Youden’s-Index) 
1 Number allergens for which the skin prick test is positive: wheel size ≥3 
2 Cumulative wheel size 
  
Sensitivity analysis 
In the sensitivity analysis with asthma diagnosis based on the pre BPTs report form, frequent wheeze 
and wheeze triggered by pollen or by pets in the past 12 months had the highest Youden’s Index, which 
was in line with the main analysis. Night cough and hay fever also had a high Youden’s index for the 
asthma diagnosis pre BPTs (table S3), but not for the asthma diagnosis post BPTs (table 2).  
For the diagnostic tests, the Youden’s index was highest at the same cut-offs for most tests (table S4 
and Figure S1). Cut-offs were higher for FeNO (25 vs. 21) and lower for BPT by exercise (6 vs. 8), FEV1 (-
0.6 vs. -0.8) and bronchodilator reversibility (2 vs. 10).  
The accuracy was higher for spirometry (AUC 0.71 and 0.65 versus 0.66 and 0.62 post BPT) and 
bronchodilator reversibility (AUC 0.72 versus 0.58 post BPT) and lower for the BPTs (AUC 0.70, 0.68 and 
0.60 versus 0.74, 0.81 and 0.68 post BPT). Accuracy was best for FeNO measurement, bronchodilator 
reversibility, FEV1/FVC and BPT by methacholine and by exercise (AUC 0.78, 0.72, 0.71, 0.70, 0.70). 
 
Discussion 
This is the first study that systematically assessed the diagnostic accuracy of reported symptoms and a 
range of tests in asthma diagnosis in children compared to a defined reference standard (doctor 
diagnosed asthma based on all available measurements and information). The main analysis and 
sensitivity analysis showed broadly comparable results, suggesting that a history of frequent wheeze, 
awakening due to wheeze and wheeze triggered by pollen or pets, FeNO measurement, BPT by 
methacholine and BPT by exercise have the best ability to distinguish asthma from no asthma. FEV1, 
FEV1/FVC and bronchodilator reversibility had a low accuracy. 
 
Only three other studies assessed the accuracy of symptoms to diagnose asthma in school-aged children 
consecutively referred to paediatric hospitals [20-22]. They all found that reported wheeze was 
sensitive (ranging 0.75-0.86) but not specific (0.64-0.73) and that frequent wheeze and awakening due 
to dyspnoea were specific (0.84-0.90) but not sensitive (0.33-0.54), which is in line with our findings. 
Symptom definitions differed between studies, especially those for cough, which results in a wide range 
of sensitivities and specificities that cannot be compared [20-22]. Five other studies assessed the 
accuracy of diagnostic tests in school aged children. Woo et al. found that a positive skin prick tests 
were sensitive but not specific (sensitivity/specificity 0.68/0.32) and that FeNO had the best cut-off at 
22 ppb (0.57/0.87), which was comparable with our study (21ppb, 0.59/0.87)) [23]. Grzelewski et al. 
found that a FEV1/FVC ratio of <80% was specific (0.91), but not sensitive (0.12) for asthma, which is in 
line with our findings (<79%, 0.90, 0.46) [24]. For the bronchodilator reversibility test, Galant et al. and 
Dundas et al. found a 9% increase in FEV1 to be the best cut-off to diagnose asthma, which is in line 
with our finding (10%), however they compared children with asthma to healthy children [25, 26]. For 
BPT by exercise, Avital et al. found an 8% decrease in FEV1 to be the best cut-off for asthma diagnosis, 
which is the same as we found [27]. For BPT by methacholine, Zaczeniuk et al. reported a cut off of <0.7 
mg as best, which was in line with our study [28]. Anderson et al found a sensitivity of 0.63 and 
specificity of 0.81 for the widely used best cut off of <635 mg for BPT by mannitol, while we found a 
lower sensitivity and higher specificity (0.43 and 0.93 respectively) [29].  
 
The recent NICE asthma diagnostic algorithm has been questioned in children. Murray et al. tested the 
algorithm in the Manchester Asthma and Allergy Study, a population-based cohort of 1184 children 
aged 13-16 years of which 89 were symptomatic but not regularly inhaling corticosteroids [5]. However, 
the Manchester study relied on parent-reported data to define asthma (reported wheeze and asthma 
treatment in the past 12 months plus a doctor diagnosis of asthma ever in life) and compared children 
with asthma to healthy children, leaving out from the analysis all those with possible asthma. In clinical 
practice we want to distinguish children with asthma from children with respiratory symptoms due to 
other causes, not from healthy children. If we would have applied the NICE algorithm to our clinical 
population, only 4 of the 111 children would have been diagnosed with asthma at the initial visit 
(FEV1/FVC <70% and bronchodilator responsibility of ≥12%). 106 would have needed 2 weeks peak 
expiratory flow monitoring followed by a second visit. We also found that less stringent cut off values 
had higher sensitivity and specificity than those recommended by the NICE algorithm (FEV1/FVC <80% 
vs. <70%, bronchodilator reversibility ≥10% vs. ≥12% and FeNO ≥26ppb vs. ≥35ppb, respectively). This 
highlights the need to base diagnostic algorithms for children on clinical studies done in children, rather 
than in adults. 
 
A main strength of our study is that it represents a real-life situation in everyday paediatric practice. 
With this clinical design, it reflects the typical mix of patients in a paediatric outpatient clinic. All 
children were first-time referrals for evaluation of possible asthma, which is the patient group 
diagnostic tests are intended for. Therefore, the study population is representative of daily clinical 
practice, in contrast to many published studies that selectively include well-defined moderate to severe 
asthmatics comparing them to healthy controls and excluding patients with unclear degrees of airway 
reactivity. In addition, our patients had an extensive array of examinations for lung function, BPT and 
allergy, which allowed us to assess the accuracy of different symptoms and diagnostic tests 
simultaneously.  
 
An important limitation of this study was that the reference standard for asthma diagnosis (the final 
diagnosis by the physician) took into account the results of the patient history and diagnostic tests for 
which the accuracy was assessed. However, as there is no single objective test to diagnose asthma and 
be used as a comparator, the clinician’s judgement, taking into account the full history, examination and 
test results, is the best we can do. The sensitivity analysis using the physicians’ diagnosis before BPTs 
were performed, showed comparable results. The small differences, however, highlight the dependence 
of the physician’s diagnosis on the array of tests done. The reference diagnosis of asthma was made by 
experienced paediatric pulmonologists (3 in Basel and 2 in St. Gallen), trained in Switzerland, who met 
several times prior to and during the study to standardise their procedures and minimise centre specific 
effects. In this study we restricted analysis to basic clinical tests. The advantage of this approach is that 
most of these tests are available in clinical routine. However, future studies should also evaluate the 
diagnostic accuracy of newer techniques such as component-resolved IgE diagnostic, multiple breath or 
single-breath washout techniques. 
 
Our findings, which need to be replicated in other populations of patients, will help to propose a more 
evidence based paediatric diagnostic algorithm, which incorporates both information on symptoms and 
objective measures. This might be helpful in reducing the need for trials of asthma treatment, which can 
be costly, time consuming and can lead to misdiagnosis and overtreatment. Our study is therefore an 
important contribution to the small body of evidence about the value of different tests for the diagnosis 
of paediatric asthma on which guidelines should be based. Mild paediatric asthma is a disease with 
highly variable activity and paroxysmal clinical manifestation. It seems unlikely that any test performed 
at a specific time point will be accurate enough to either prove or exclude reactive airway disease. 
Future studies should ideally be larger, to allow analysing the value of combination of several tests, and 
focus on children newly referred for evaluation of possible asthma, and be referenced to a clearly 
defined and robust reference diagnosis.  
Our results suggest that, until more evidence is available, diagnosis of asthma in school aged children 
should rely primarily on reported triggers and severity of wheeze and results of FeNO, and if available 
methacholine and exercise challenge testing which were most accurate in our study. 
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Figure 1. Study procedures. The report form is a standardised form for physicians to note down the 
clinical diagnosis. BPT: bronchial provocation test. Bronchodilator rev.: Bronchodilator reversibility. 
*Children who received salbutamol after the exercise BPT conducted the methacholine BPT at an 
extra visit.  Between visits the family completed a questionnaire. 
 
 
 
Figure 2 Receiver operating characteristics (ROC) curve of clinical tests to diagnose asthma.  
* Cut-off with maximum combined sensitivity and specificity 
Test    Unit 
SPT number positive  decrease of 1 positive skin prick test 
SPT cumulative wheel size  decrease of 1 mm cumulative wheel size  
FeNO    decrease of 1 parts per billion (ppb) 
FEV1     increase of 0.1 z-score 
FEV1/FVC    increase of 1% 
Bronchodilator reversibility increase of 1% in FEV1 
Exercise    decrease of 1% in FEV1 
Methacholine    increase of 0.1 mg methacholine 
Mannitol   increase of 5 mg mannitol 
 
 
 
* 
Supplementary text: 
Methods of bronchial provocation tests 
For all bronchial provocation tests, baseline FEV1 was measured in triplicate using ATS 
criteria for paediatric lung function testing [1] and the best measurement was recorded. 
Children were excluded from the challenge if their baseline FEV1 was ≤65% of predicted or if 
they were unwilling to cooperate. If 15 minutes after the bronchial provocation test, FEV1 
had not returned within 5% of baseline or in case of dyspnoea, salbutamol 100 µg (2-4 puffs 
Ventolin® pMDI via spacer) was given to reverse the bronchoconstriction. 
 
Exercise provocation test 
The children performed the exercise challenge using a treadmill (T-2100, GE Healthcare, 
Freiburg, Germany) or a bicycle ergometer (ER Ergoselect 200, Ergoline GmbH, Bitz, 
Germany) for 8 min, inspiring room air according to published ATS and ERS guidelines [2, 3]. 
At one site, children chose between treadmill and bicycle, at the other only a treadmill was 
available. We performed exercise testing under controlled conditions (maintaining inspired 
air temperature at 20–25°C and humidity of <10 mg water/L) [4] and measured heart rate 
and oxygen saturation by pulse oximeter with a forehead sensor (Nellcor N595 OxiMax, 
Tyco Healthcare, Neustadt/Donau, Germany). After baseline spirometry we started exercise 
testing at 60% target workload (defined as Watt = measured FEV1 x 53.76-11.07), rapidly 
increasing workload aiming at 75% of the target in the second minute, 90% in the third 
minute, and 100% in the fourth minute, sustaining the latter for ³4 min. We increased 
workloads more rapidly if the heart rate was not expected to reach at least 85% of the 
predicted maximum (220-age in years).[2] Spirometry was performed 1, 3, 5, 7, 10, and 15 
min after exercise, in duplicate [5].  
We reported the results as the maximum fall of FEV1 during the exercise provocation test. 
Methacholine provocation test 
The children performed the methacholine provocation test based on the Five-Breath 
Dosimeter Protocol [2, 4]. They first inhaled NaCL 0.9% to measure baseline values, then 
they inhaled stepwise 0.05mg, 0.05mg, 0.2mg, 0.3mg, 0.6mg and 1.2mg of methacholine 
(cumulative dose of 2.4 mg in children <14 years old) via a nebulizer. Children older than 14 
years old had an additional inhalation step with a cumulative dose of 3.2mg methacholine. 
At end exhalation during tidal breathing, the children inhaled slowly and deeply from the 
nebulizer. The dosimeter was triggered after the inhalation begins, and the subject was 
encouraged to continue inhaling slowly and to hold the breath for another 5 seconds. This 
step was repeated for a total of five inspiratory capacity inhalations which should not take 
more than 2 minutes. The challenge was terminated when FEV1 fell by 20% or more, or the 
highest dose was given. Lung function was measured in 5-min intervals until it had returned 
to within 5% of the baseline value. We reported the results of the methacholine provocation 
test as provocation dose causing a 20% decrease of FEV1 from baseline (PD-20). 
 
Mannitol dry powder provocation test 
The mannitol provocation test was performed according to the protocol recommended by 
Anderson et al. [6], with slight modifications [7, 8]. Baseline FEV1 was measured in triplicate 
and the highest of these measures was recorded. The mannitol dry powder (MDP) 
provocation test (AridolTM, Pharmaxis, French Forests, New South Wales, Australia) was 
conducted as described in our previous study [8]. The children were asked to inhale the 
contents of an MDP capsule through the delivery device (OsmohalerTM). The following 
dosing steps were used: 0 mg (empty capsule acting as a placebo to measure baseline FEV1), 
5, 10, 20, 40, 80, 160, 160, and 160 mg. We administered multiples of 40 mg capsules to 
achieve doses of 80 mg and more. After each dose, children performed a 5-sec breath-hold, 
followed one minute later by spirometry in duplicate, and the higher FEV1 was recorded. If 
the children had a decrease in FEV1 >10%, then the dose producing this was repeated for 
safety reasons. This process was repeated until either FEV1 had fallen by 15% or the subject 
had reached the maximum dose (cumulative dose of 635 mg mannitol). We reported the 
results of the mannitol provocation test as provocation dose causing a 15% decrease of FEV1 
from baseline (PD-15). 
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Supplementary tables and figure 
 
Table S1. Diagnoses in children with suspected asthma N=111 
 Diagnoses 
pre-BPTs1 
n (%) 
 Diagnoses 
post-BPTs1 
n (%) 
Definite diagnoses 79 (71)  97 (87) 
     Asthma 65 (59)  68 (61) 
     Cough not due to asthma 9 (8)  14 (13) 
     ILO2/vocal cord dysfunction 3 (3)  6 (5) 
     Functional symptoms / hyperventilation 0 (0)  7 (6) 
     Adenoid hyperplasia with OSAS3 1 (1)  1 (1) 
     Recurrent colds 1 (1)  1 (1) 
Probable diagnoses 32 (29)  14 (13) 
     Asthma 29 (26)  12 (11) 
     ILO2/vocal cord dysfunction 3 (3)  2 (2) 
1 Bronchial Provocation Tests 
2 Inducible Laryngeal Obstruction 
3 Obstructive Sleep Apnoea Syndrome 
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Table S2. Diagnostic test results in patients with and without asthma N=111 
 Asthma    
 
 
Diagnostic tests 
Definite asthma  
N=68 
median (IQR) 
 Other diagnosis 
N=31 
median (IQR) 
 Probable asthma 
N=12 
median (IQR) 
Skin prick test (N=107)         
     ≥1 positive test n(%) 29 (43)  7 (23)  5 (42) 
     Number of positive tests* 3 (2-4)  2 (0-3)  2 (1-3) 
     Cum wheel size in mm± 9 (5-14)  5 (0-8)  7 (0-9) 
FeNO (N=111)         
     Parts per billion 30 (14-62)  10 (6-16)  14 (9-22) 
Spirometry (N=111)         
     FEV1, z-scores     -0.5 (-1.2-0.3)  -0.1 (-0.5-0.4)  -1.0 (-2.2--0.2) 
     FEV1/FVC 83 (75-89)  87 (83-90)  78 (71-89) 
Bronchodilator rev. (N=103)         
     Increase in FEV1 in % 4 (-5-14)  1 (-5-8)  3 (-1-6) 
Bronchial provocation test         
Exercise (N=99)         
     Decrease in FEV1 in %° 12 (6-19)  4 (1-7)  5 (1-6) 
Methacholine (N=104)         
     Provocation dose in mg“ 0.1 (0.1-0.3)  2.4 (0.3-3.2)  0.3 (0.1-1.6) 
Mannitol (N=111)         
     Provocation dose in mg# 635 (190-635)  635 (635-635)  635 (635-635) 
° median (and inter quartile range) fall in FEV1 during exercise  
“ median (and inter quartile range) provocation dose for a fall of ≥ 20% in FEV1 (PD-20) 
# median (and inter quartile range) provocation dose for a fall of ≥ 15% in FEV1 (PD-15) 
* Wheal size ≥3mm 
± Cumulative wheel size in mm 
Bronchodilator rev. = Bronchodilator reversibility 
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Table S3. Sensitivity analysis of diagnostic accuracy of respiratory symptoms to diagnose 
asthma pre-BPTs N=111 
 A+S+ 
n 
A-S+ 
n 
A+S- 
n 
A-S- 
n 
Sens 
%  
(95%CI) 
Spec 
%  
(95%CI) 
PPV 
%  
(95%CI) 
NPV 
%  
(95%CI) 
YI 
Respiratory symptoms 
in the past 12 months 
         
Any wheeze 69 11 25 6 73 (63-82) 35 (14-62) 86 (77-93) 19   (7-37) 0.08 
> 3 attacks of wheeze 36 2 58 15 38 (28-49) 88 (64-99) 95 (82-99) 21 (12-32) 0.26 
Wheeze with colds 36 7 58 10 38 (28-49) 59 (33-82) 84 (69-93) 15   (7-25) -0.03 
Wheeze apart from colds 59 8 35 9 63 (52-73) 53 (28-77) 88 (78-95) 20 (10-35) 0.16 
Exercise-induced wheeze 62 8 32 9 66 (55-75) 53 (28-77) 89 (79-95) 22 (11-38) 0.19 
Wheeze triggered by          
     Pollen 34 2 47 14 42 (31-53) 88 (62-98) 94 (81-99) 23 (13-35) 0.30 
     House dust 20 1 58 14 26 (16-37) 93 (68-99) 95 (76-99) 19 (11-30) 0.19 
     Pets 20 0 57 10 26 (17-37) 99 (69-99) 99 (83-99) 15   (7-26) 0.25 
Awakening due to wheeze 33 3 61 14 35 (26-46) 82 (57-96) 92 (78-98) 19 (11-29) 0.17 
Cough > 4 weeks 14 7 79 10 15   (8-24) 59 (33-82) 67 (43-85) 11   (6-20) -0.26 
Night cough 45 3 49 13 48 (37-58) 81 (54-96) 94 (83-99) 21 (12-33) 0.29 
Cough more than others 32 5 61 12 34 (25-45) 71 (44-90) 86 (71-95) 16   (9-27) 0.05 
Dyspnoea 23 2 69 15 25 (17-35) 88 (64-99) 92 (74-99) 18 (10-28) 0.13 
Hay fever 46 3 46 14 50 (39-61) 82 (57-96) 94 (83-99) 23 (13-36) 0.32 
Eczema 24 2 68 15 26 (17-36) 88 (64-99) 92 (75-99) 18 (10-28) 0.14 
A+S+ = children with asthma diagnosis and reported symptom, A-S+ = children without asthma diagnosis but with 
symptom, A+S- = children with asthma diagnosis but without symptom, A-S- = children without asthma and 
without symptom, Sens = sensitivity, Spec = specificity, PPV = positive predictive value, NPV = negative predictive 
value YI = Youden’s-Index = Sensitivity + Specificity -1 
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Table S4. Sensitivity analysis of diagnostic accuracy of clinical tests to diagnose asthma pre BPTs 
N=111 
 A+T+ 
n 
A-T+ 
n 
A+T- 
n 
A-T- 
n 
Sens 
%  
(95%CI) 
Spec 
%  
(95%CI) 
PPV 
%  
(95%CI) 
NPV 
%  
(95%CI) 
YI AUC 
Clinical tests           
Skin prick test1          0.69 
     ≥1 positive test 79 8 12 8 87 (78-93) 50 (25-75) 91 (83-96) 40 (19-64) 0.37  
     ≥2 positive tests* 70 5 21 11 77 (67-85) 69 (41-89) 93 (85-98) 34 (19-53) 0.46  
Skin prick test2          0.69 
     ≥4 mm* 73 6 16 10 82 (72-89) 63 (35-85) 92 (84-97) 38 (20-59) 0.45  
     ≥8 mm 49 4 40 12 55 (44-66) 75 (48-93) 92 (82-98) 23 (13-37) 0.30  
FeNO          0.78 
     ≥21ppb 49 2 45 15 52 (42-63) 88 (64-99) 96 (87-99) 25 (15-38) 0.40  
     ≥22ppb 46 2 48 15 49 (38-59) 88 (64-99) 96 (86-99) 24 (14-36) 0.37  
     ≥25ppb* 42 0 52 17 45 (34-55) 99 (80-99) 99 (91-99) 25 (15-36) 0.44  
     ≥35ppb 33 0 61 17 35 (26-46) 99 (80-99) 99 (89-99) 22 (13-33) 0.34  
Spirometry           
  FEV1/FVC          0.71 
     <70% 6 0 88 16 6   (2-13) 99 (79-99) 99 (54-99) 15   (9-24) 0.06  
     <80% 39 0 55 16 41 (31-52) 99 (79-99) 99 (91-99) 23 (13-34) 0.41  
     <81%* 40 0 54 16 43 (32-53) 99 (79-99) 99 (91-99) 23 (14-34) 0.43  
     <90% 77 11 17 5 82 (73-89) 31 (11-59) 88 (79-94) 23   (8-45) 0.13  
  FEV1          0.65 
     ≤-0.6* 45 2 49 15 48 (38-58) 88 (64-99) 98 (85-99) 23 (14-36) 0.36  
     ≤-0.8 40 2 54 15 43 (32-53) 88 (64-99) 95 (84-99) 22 (13-33) 0.31  
     ≤-1.0 31 2 63 15 33 (24-43) 88 (64-99) 94 (80-99) 19 (11-30) 0.21  
Bronchodilator rev.          0.72 
  ≥2% increase FEV1* 55 3 32 13 63 (52-73) 81 (54-96) 95 (86-99) 29 (16-44) 0.44  
  ≥10% increase FEV1 23 0 64 16 26 (18-37) 99 (79-99) 99 (85-99) 20 (12-30) 0.26  
  ≥12% increase FEV1 19 0 68 16 22 (14-32) 99 (79-99) 99 (82-99) 19 (11-29) 0.22  
BPT           
 Exercise          0.70 
   ≥6% decrease FEV1* 57 3 29 10 66 (55-76) 77 (46-95) 95 (86-99) 26 (13-42) 0.43  
   ≥8% decrease FEV1 49 3 37 10 57 (46-68) 77 (46-95) 94 (84-99) 21 (11-36) 0.34  
   ≥10% decrease FEV1 40 3 46 10 47 (36-58) 77 (46-95) 93 (81-99) 18   (9-30) 0.24  
   ≥12% decrease FEV1 32 3 54 10 37 (27-48) 77 (46-95) 91 (77-98) 16   (8-27) 0.14  
 Methacholine          0.68 
   PD-20 <0.6mg* 65 5 23 11 74 (63-83) 69 (41-89) 93 (84-98) 32 (17-51)   
   PD-20 <0.7mg 67 6 21 10 76 (66-85) 63 (35-85) 92 (83-97) 32 (17-51) 0.43  
   PD-20 <1mg 67 6 21 10 76 (66-85) 63 (35-85) 92 (83-97) 32 (17-51) 0.39  
 Mannitol          0.60 
   PD-15 <635 mg* 30 2 64 15 32 (23-42) 88 (64-99) 94 (79-99) 19 (11-29) 0.20  
A+T+ = children with asthma diagnosis and positive test result, A-T+ = children without asthma diagnosis but 
positive test result, A+T- = children with asthma diagnosis but negative test result, A-T- = children without asthma 
and negative test result, Sens = sensitivity, Spec = specificity, PPV = positive predictive value, NPV = negative 
predictive value, YI = Youden’s-Index = Sensitivity + Specificity -1, AUC = area under the curve, FeNO = fractional 
exhaled nitric oxide, ppb = parts per billion, FEV1 = forced expiratory volume in 1 second, FVC = forced vital 
capacity, Bronchodilator rev. = bronchodilator reversibility, BPT = bronchial provocation test  
Cut-offs chosen based on proposed cut-offs from previous publications 
*Cut-off with maximum combined sensitivity and specificity (highest Youden’s-Index) 
1 Number allergens for which the skin prick test is positive: wheel size ≥3 
2 Cumulative wheel size  
5 
 
 
Figure S1 Receiver operating characteristics (ROC) curve of clinical tests to diagnose asthma. 
(Sensitivity analysis: pre-BPTs) * Cut-off with maximum combined sensitivity and specificity 
Test    Unit 
SPT number positive  decrease of 1 positive skin prick test 
SPT cumulative wheel size  decrease of 1 mm cumulative wheel size  
FeNO    decrease of 1 parts per billion (ppb) 
FEV1     increase of 0.1 z-score 
FEV1/FVC    increase of 1% 
Bronchodilator reversibility increase of 1% in FEV1 
Exercise    decrease of 1% in FEV1 
Methacholine    increase of 0.1 mg methacholine 
Mannitol   increase of 5 mg mannitol
Supplementary questionnaire 2 
Baseline questionnaire, English translation 
 
Questionnaire on breathing and allergies 
How to fill it in? yes  no  = please, tick the appropriate box 
|15 |10 |1998| = please, fill out 
__________ = please, write words 
 
General questions 
Date questionnaire completed: |___|___|____| 
                                                   day month year 
Person completing questionnaire: 
(tick all who helped to fill in) 
mother  father  child  other  __________ 
    
Last name ___________________________________________________________________________ 
First name ___________________________________________________________________________ 
Birthdate |___|___|____| 
  day month year 
Sex male  female  
    
Part 1  
1. In the last 12 months, how many times have you had a cold or flu? 
 
None  1-3  4-6  7-9  10 or more  
 
2. How long does a cold usually last? 
 
Less than a week  1-2 weeks  2-4 weeks  More than 4 weeks  
 
3. In the last 12 months, have you had a cough that lasted more than 4 weeks? 
 
yes  no  
 
4. In the last 12 months, have you had a dry cough at night, apart from a cough 
associated with a cold or a chest infection? 
 
yes  no  
 
5. Do you think that you cough more than other children your age? 
 
yes  no  
 
Part 2 
6. Have you ever had wheezing or whistling in the chest at any time in the past? 
 
yes  no  
 
7. Have you had wheezing or whistling in the chest in the last 12 months? 
 
yes  no  
 
If you answered “no” to both questions, please skip to part 3. 
 
8. How many attacks of wheezing have you had during the last 12 months? 
 
None  1-3 times  4-12 times 
 
More than 12 times  
 
9. In the last 12 months, have you had wheezing or whistling in the chest during or 
soon after a cold or flu? 
 
yes  no  
 
10. In the last 12 months, have you had wheezing or whistling in the chest without 
having a cold or flu? 
 
yes  no  
 
11. In the last 12 months, has your chest sounded wheezy during or after exercise? 
 
yes  no  
 
12. In the last 12 months, which of the following things caused you to wheeze 
 
- Exercise (running, sports) yes  no  Don’t know  
- Laughing or crying yes  no  Don’t know  
- Pollen (grass, hay, trees, flowers) yes  no  Don’t know  
- House dust yes  no  Don’t know  
- Contact with pets or other animals yes  no  Don’t know  
- Foods or drinks yes  no  Don’t know  
 
13. In the last 12 months, how often, on average, has your sleep been disturbed due 
to wheezing? 
 
Never woken up  Less than one night per week  One or more nights per week  
 
14. In the last 12 months, has wheezing ever been severe enough to limit your speech 
to only one or two words at a time between breaths? 
 
yes  no  
 
15. Have you ever had asthma? 
 
yes  no  
 
16. Do you need to use medication because of these breathing problems? 
 
yes  no  
  
- If yes, how regularly? 
 
 
Sometimes (less than once per week)  Regularly (1-6 times per week)  Daily  
   
- If yes, which medication?      _______________________________________ 
 
 
17. In the last 12 months, how much did cough, wheezing or breathlessness interfere 
with your daily activities (at home or while playing with other kids) 
 
Practically daily  
 
About once a week  About once per month  
Less than once per month  Never  Don’t know  
 
18. In the last 12 months, how much did cough, wheezing or breathlessness interfere 
with your sport activities? 
 
Practically daily  
 
About once a week  About once per month  
Less than once per month  Never  Don’t know  
 
 
Part 3 
19. In the last 12 months, have you had a problem with sneezing or a runny or blocked 
nose when you did not have a cold or flu? 
 
yes  no  
 
20. In the last 12 months, has this nose problem been accompanied by itchy-watery 
eyes? 
 
yes  no  
 
21. In which of the last 12 months, did these problems occur? 
 
January  February  March  April  
May  June  July  August  
September  October  November  December  
 
22. In the last 12 months, how much did these problems interfere with your daily 
activities? 
 
Not at all  A little  Moderately  Very much  
 
23. Have you ever had hay fever? 
 
yes  no  
 
Part 4 
24. Have you ever had an itchy rash, which was coming and going for at least six 
months? 
 
yes  no  
 
25. Have you had this itchy rash at any time in the last 12 months? 
 
yes  no  
 
26. Has this itchy rash affected any of the following places: the folds of the elbows, 
behind the knees or around the neck, ears or eyes? 
 
yes  no  
  
-If yes, which places were affected by this itchy rash? _______________________ 
 
 
27. Has this rash cleared completely at any time during the last 12 months? 
 
yes  no  
 
28. In the last 12 months, how often, on average, have you been kept awake at night 
by this itchy rash? 
 
Never in the last 12 months  Less than 1 night per week  One or more nights per week  
 
29. Have you ever had eczema? 
 
yes  no  
 
Part 5 
30. Did you ever have problems with your heart? 
 
yes  no  
 
31. What kind of heart problems? 
 
Arrhythmia  Congenital heart defect   Other   ________________ 
 
32. Did you ever have to take medication for your heart? 
 
yes  no  
 
 
33. Did you ever have a heart surgery? 
 
yes  no  
 
34. Do your heart problems still interfere with your daily activities? 
 
yes  no  
 
Part 6 
35. Who smokes in your household? 
 
Father yes  no  
Mother yes  no  
Other adult yes  no  
Children yes  no  
 
36. How many cigarettes in total are being smoked in your house per day? 
 
None   1-10  11-20  21-40  Über 40  
 
37. Do you smoke yourself? 
 
Yes, I smoke sometimes  Yes, I have tried it once or twice, 
but I don’t smoke regularly  
No, I have never smoked  
 
- If yes, how many packages do you smoke per week? ____________________ 
 
- If yes, since how many months do you smoke? _________________________ 
 
Comment box 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Thank you for completing the questionnaire! 
 
 
